skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

Neuropsychiatric Disease and Treatment

(2,361,178) Views

Editor in Chief Dr Roger M Pinder

1176-6328


Letter: Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
Fumihiko Okada

Neuropsychiatric Disease and Treatment 2007, 3:181-182
18 May 2007


Letter: Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients
Takahiko Nagamine

Neuropsychiatric Disease and Treatment 2007, 3:177-179
18 May 2007


Aripiprazole treatment of Asperger’s syndrome in the acute psychiatric setting: case report
Luiz Dratcu, Gavin McKay, Vinod Singaravelu, Venkat Krishnamurthy
Neuropsychiatric Disease and Treatment 2007, 3:173-176
18 May 2007


A survey of five antidepressant properties influencing clinician’s treatment choices in MDD
George I Papakostas, Lindsay A Hallett, Juliana Smith, Eliana Tossani, Alessandra Mascarini, Alana M Burns, Robert J Birnbaum, Maurizio Fava, Jonathan E Alpert
Neuropsychiatric Disease and Treatment 2007, 3:169-172
18 May 2007


The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists
Michael A Shapiro, Yu Ling Chang, Sarah K Munson, Charles E Jacobson IV, Ramon L Rodriguez, Frank M Skidmore, Michael S Okun, Hubert H Fernandez

Neuropsychiatric Disease and Treatment 2007, 3:161-167
18 May 2007


One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters)
Eva Cešková, Prikryl Radovan, Kašpárek Tomáš, Kucerová Hana
Neuropsychiatric Disease and Treatment 2007, 3:153-160
18 May 2007


Prodromal non-motor symptoms of Parkinson’s disease
Clelia Pellicano, Dario Benincasa, Vincenzo Pisani, Francesca R Buttarelli, Morena Giovannelli, Francesco E Pontieri
Neuropsychiatric Disease and Treatment 2007, 3:145-151
18 May 2007


The schizophrenias, the neuroses and the covered wagon; a critical review
C Raymond Lake, Nathaniel Hurwitz

Neuropsychiatric Disease and Treatment 2007, 3:133-143
18 May 2007


Managing patient adherence and quality of life in epilepsy
Joanne Eatock, Gus A Baker

Neuropsychiatric Disease and Treatment 2007, 3:117-131
18 May 2007


Impaired cognition and attention in adults: pharmacological management strategies
Hervé Allain, Yvette Akwa, Lucette Lacomblez, Alain Lieury, Danièle Bentué-Ferrer
Neuropsychiatric Disease and Treatment 2007, 3:103-116
18 May 2007


Patterns of anterior cingulate activation in schizophrenia: a selective review
Rick Adams, Anthony S David
Neuropsychiatric Disease and Treatment 2007, 3:87-101
18 May 2007


Ziconotide: a review of its pharmacology and use in the treatment of pain
Joseph G McGivern

Neuropsychiatric Disease and Treatment 2007, 3:69-85
18 May 2007


Venlafaxine in the treatment of panic disorder
Martin A Katzman, Leslie Jacobs

Neuropsychiatric Disease and Treatment 2007, 3:59-67
18 May 2007


Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
Teruhiko Higuchi, Mike Briley
Neuropsychiatric Disease and Treatment 2007, 3:41-58
18 May 2007


Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long acting atypical antipsychotic
Pierre Chue

Neuropsychiatric Disease and Treatment 2007, 3:13-39
18 May 2007


Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
Gerhard Kluger, Bettina Bauer

Neuropsychiatric Disease and Treatment 2007, 3:3-11
18 May 2007


Editorial: Pathological gambling and dopamine agonists: A phenotype? || FREE PAPER ||
Roger M Pinder

Neuropsychiatric Disease and Treatment 2007, 3:1-2
18 May 2007